Last reviewed · How we verify
NCT07092605
Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures
EARLY_PHASE1 trial testing GLP-1 in Longevity in 150 participants. Enrolling by invitation.
1 November 2025
Quick facts
| Lead sponsor | AgelessRx |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 1 November 2024 |
| Primary completion | 1 November 2025 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- GLP-1 — full drug profile →
- Placebo
Conditions studied
- Longevity — all drugs for Longevity →
- Quality of Life — all drugs for Quality of Life →
- Mood — all drugs for Mood →
- Inflammation — all drugs for Inflammation →
Sponsor
AgelessRx — full company profile →
Who can join
Adults 18 to 65, any sex, with Longevity or Quality of Life. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity. The Secondary Objective: To assess the impact of these therapies on weight management practices and metabolic health.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07092605
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of GLP-1
Trials testing the same drug.
- NCT07207148 — People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists · recruiting
- NCT07042672 — Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity · recruiting
- NCT07368855 — GLP-1 Medicines and Mental Health Changes · NA · completed
- NCT03702660 — Effect of GIP After a Meal in Patients With Type 2 Diabetes · NA · completed
- NCT03195257 — Glucose-Dependent Insulinotropic Polypeptide - Effects on Markers of Bone Turnover in Patients With Type 1 Diabetes · NA · completed
Other recruiting trials for Longevity
Currently open trials in the same condition.
- NCT07322406 — Kaempferol Absorption and Pharmacokinetics Evaluation · NA · recruiting
Other AgelessRx trials
Trials by the same sponsor.
- NCT06301529 — The Efficacy and Tolerability of Canagliflozin in Healthy Individual · Phase 4 · completed
- NCT06550271 — The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals · completed
- NCT05542849 — The Efficacy and Tolerability of Acarbose in Healthy Individuals · Phase 4 · completed
- NCT05307627 — The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging · withdrawn
- NCT04604704 — Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07092605 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AgelessRx
- Last refreshed: 30 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07092605.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing